Replies to post #315145 on Avid Bioservices Inc (CDMO)

[CHEVYGUY]

Thats because nothing you say comes true so we figured we would wait for short totals or the imminent or soon part.

[BioBS2012]

Just for fun - anyone care to opine on what would happen to the share price immediately AFTER a PR announcing an MSK purchase of a 1% interest {approx 450,000 shares for around $2 Million} in PPHM - along with placing their representative on the BOD - thus formalizing their relationship with PPHM - and thereby immediately VALIDATING the IP ??

I won't opine about the share price because, really, who the heck knows. However, as to MSK investing $2 MM in $PPHM - ROFLMAO is the least I can do.
Here is an institution that has its mouth on the $PPHM teat, and suddenly they are going to offer their teat to $PPHM?? Well I guess it is good to dream.
Any ways that is IMO.

Cheers.

[The Other Guy]

Best thing is if
I can have a Peregrine manager
Take a nice picture or
Eat a sandwich on the beach.

My guess is it won’t
Even happen tomorrow.

[corporalagarn]

Anyone care to opine what would happen if the sun rose in the west tomorrow? That would be cool. Wrong since 2008. What a streak.

[biopharm]

James, my concern would be if Peregrine is bring sought after by a Big Pharma and that Big Pharma uses a subsidiary company to go after Peregrine and some things to think about would be PS Targeting becoming restricted and held back and not being able to capitalize on future milestones / royalties ...etc from the same Big Pharma controlling the subsidiary in various ways...

A deal could sound tempting at first ...upfront cash and matching shares ...and maybe even a private company looking to go public and rolling Peregrine right into them...

Lots of possibilities and back to your post regarding MSK and their venture arm; just makes me think that Ludwig Dr Cerundolo and Dr Wolchok would likely be involved as like iTeo


http://www.ludwigcancerresearch.org/news/ludwig-cancer-research-and-university-oxford-launch-cancer-immunotherapy-spinout

http://www.iteostherapeutics.com/about-us/scientific-committee

----

iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for Discovery and Development of Cancer Immunosuppression Targets
Dec 08, 2014, 02:30 ET from iTeos Therapeutics SA
..
..
...
"This strategic collaboration is a transformative opportunity for iTeos," said Michel Detheux, Ph.D., chief executive officer of iTeos. "The oncologic expertise of Pfizer will help enable the acceleration and expansion of the scope of iTeos' IDO1 and TDO2 programs. Furthermore, by working with Pfizer, we aim to produce a series of new targets that have the potential to be further developed by iTeos or Pfizer. This expansion of our drug discovery programs is expected to provide additional, novel immunomodulators for future treatment of cancer patients. The successful integration of Ludwig Cancer Research science into iTeos' preclinical discovery platform in just two years following inception of the company made this collaboration possible."

"This collaboration with iTeos is another important step for Pfizer as we continue to build an industry-leading pipeline of cancer immunotherapeutics, a critical facet of which is the promising class of small molecule immunomodulators," said Robert Abraham, Ph.D., Senior Vice President and Chief Scientific Officer, Oncology Research Unit, Pfizer. "With iTeos' strong expertise and experience in tumor immunology, this collaboration is well-positioned to help us deliver on our commitment to help bring new therapies to patients."

iTeos will receive from Pfizer an up-front payment of € 24 million, plus an equity investment, licensing fees and collaborative funding. Further, iTeos will be eligible to earn potential milestone payments from Pfizer based on the achievement of specific development, regulatory and commercial milestones across the IDO1 and TDO2 programs, in addition to royalties on sales. iTeos also has the opportunity to earn additional milestone and royalty payments for any of the new target programs that are advanced by Pfizer.
..
..
https://www.prnewswire.com/news-releases/iteos-therapeutics-announces-license-and-collaboration-with-pfizer-inc-for-discovery-and-development-of-cancer-immunosuppression-targets-300005907.html

-------

Now it will be interesting to see how this all turns out and would a Big Pharma like Pfizer just stand back and allow PS Targeting to become wrapped up under Novartis or one of their subsidiaries ? Possibly but just thinking about matching shares with a public company subsidiary of a BP that already owns 50%+ of the subsidiary and Dr Wolchok sits on a dozen+ biotech as SA so I imagine he gets asked about PS Targeting in many places

[geocappy1]

Do you think this will happen before or after Ronin takes over Pphm? Is this another imminent event?

[geocappy1]

IMO it will take more than a $2M buy in to save this BOD and move the price. In fact, if they only spent $2M I wouldn't think they were very confident